Roles of interferon-gamma and its target genes in schizophrenia: Proteomics-based reverse genetics from mouse to human

Proteomics

Volumn 12, Issue 11, 2012, Pages 1815-1829

  Kim, Hak Jae ^a   Eom, Chi Yong ^b   Kwon, Joseph ^b   Joo, Jaesoon ^a   Lee, Sujeong ^a   Nah, Seong Su ^a   Kim, Il Chul ^c   Jang, Ik Soon ^b   Chung, Young Ho ^b   Kim, Seung Il ^b   Chung, Joo Ho ^d   Choi, Jong Soon ^b,e  

^a Soonchunhyang University   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

^c Chonnam National University   (South Korea)

^d Kyung Hee University Hospital   (South Korea)

^e Chungnam National University   (South Korea)

Author keywords

Biomedicine; Interferon gamma; Schizophrenia; Single nucleotide polymorphism

Indexed keywords

CREATINE KINASE; GAMMA INTERFERON; TRIOSEPHOSPHATE ISOMERASE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC POLYMORPHISM; HISTOCHEMISTRY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE GENETICS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ANIMALS; BRAIN; CASE-CONTROL STUDIES; CREATINE KINASE, BB FORM; DOWN-REGULATION; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEOME; PROTEOMICS; REPUBLIC OF KOREA; REVERSE GENETICS; RNA, MESSENGER; SCHIZOPHRENIA; TRIOSE-PHOSPHATE ISOMERASE; UP-REGULATION;

MUS;

EID: 84862894687     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100184     Document Type: Article

References (51)

1. Lewis, D.A., Lieberman, J.A., Catching up on schizophrenia: natural history and neurobiology. Neuron 2000, 28, 325-334.
2. Lewis, D.A., Levitt, P., Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 2002, 25, 409-432.
3. Kirch, D.G., Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 1993, 19, 355-370.
4. Rothermundt, M., Arolt, V., Weitzsch, C., Eckhoff, D. et al., Production of cytokines in acute schizophrenic psychosis. Biol. Psychiatry 1996, 40, 1294-1297.
5. Skurkovich, S.V., Aleksandrovsky, Y.A., Chekhonin, V.P., Ryabukhin, I.A. et al., Improvement in negative symptoms of schizophrenia with antibodies to tumor necrosis factor-alpha and to interferon-gamma: a case report. J. Clin. Psychiatry 2003, 64, 734-735.
6. Muller, N., Riedel, M., Ackenheil, M., Schwarz, M.J., The role of immune function in schizophrenia: an overview. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249 Suppl 4, 62-68.
7. Muller, N., Riedel, M., Ackenheil, M., Schwarz, M.J., The immune system and schizophrenia. An integrative view. Ann. NY Acad. Sci. 2000, 917, 456-467.
8. + cells in medication-free patients with schizophrenia. J. Psychiatr. Res. 2002, 36, 331-336.
9. Rothermundt, M., Aleksandrovsky, Y.A., Chekhonin, V.P., Ryabukhin, I.A. et al., Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 2000, 11, 3385-3388.
10. Na, K.S., Kim, Y.K., Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 2007, 56, 55-63.
11. Arolt, V., Rothermundt, M., Wandinger, K.P., Kirchner, H., Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol. Psychiatry 2000, 5, 150-158.
12. Clark, D., Dedova, I., Cordwell, S., Matsumoto, I., A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol. Psychiatry 2006, 11, 459-470.
13. Pennington, K., Beasley, C.L., Dicker, P., Fagan, A. et al., Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol. Psychiatry 2008, 13, 1102-1117.
14. English, J.A., Pennington, K., Dunn, M.J., Cotter, D.R., The neuroproteomics of schizophrenia. Biol. Psychiatry 2011, 69, 163-172.
15. English, J.A., Dicker, P., Foecking, M., Dunn, M.J. et al., 2D-DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009, 9, 3368-3382.
16. Kroes, R.A., Panksepp, J., Burgdorf, J., Otto, N.J. et al., Modeling depression: social dominance-submission gene expression patterns in rat neocortex. Neuroscience 2006, 137, 37-49.
17. Awata, T., Matsumoto, C., Urakami, T., Hagura, R. et al., Association of polymorphism in the interferon gamma gene with IDDM. Diabetologia 1994, 37, 1159-1162.
18. Pociot, F., Veijola, R., Johannesen, J., Hansen, P.M. et al., Analysis of an interferon-gamma gene (IFNG) polymorphism in Danish and Finnish insulin-dependent diabetes mellitus (IDDM) patients and control subjects. Danish Study Group of Diabetes in Childhood. J. Interferon Cytokine Res. 1997, 17, 87-93.
19. Pravica, V., Asderakis, A., Perrey, C., Hajeer, A. et al., In vitro production of IFN-γ correlates with CA repeat polymorphism in the human IFN-γ gene. Eur. J. Immunogenet. 1999, 26, 1-3.
20. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
21. Di Poto, C., Iadarola, P. A., Bardoni, M., Passadore, I. et al., 2-DE and MALDI-TOF-MS for a comparative analysis of proteins expressed in different cellular models of amyotrophic lateral sclerosis. Electrophoresis 2007, 28, 4320-4329.
22. Park, H.J., Rajbhandari, I., Yang, H.S., Lee, S. et al., Neuronal expression of sodium/bicarbonate cotransporter NBCn1 (SLC4A7) and its response to chronic metabolic acidosis. Am. J. Physiol. Cell Physiol. 2010, 298, C1018-C1028.
23. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., American Psychiatric Press, Washington, DC, 1994.
24. Flemenbaum, A., Zimmermann, R.L., Inter- and intra-rater reliability of the brief psychiatric rating scale. Psychol. Rep. 1973, 32, 783-792.
25. Andreasen, N.C., Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 1982, 39, 784-788.
26. McGuffin, P., Farmer, A., Harvey, I., A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch. Gen. Psychiatry 1991, 48, 764-770.
27. Rickham, P.P., Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. BMJ 1964, 2, 177.
28. Fernández, E., Collins, M.O., Uren, R.T., Kopanitsa, M.V. et al., Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. Mol. Syst. Biol. 2009, 5, 269-285.
29. Hurlock, E.C., 4th, Interferons: potential roles in affect. Med. Hypotheses 2001, 56, 558-566.
30. Kustova, Y., Sei, Y., Morse, H.C., Jr., Basile, A.S., The influence of a targeted deletion of the IFN gamma gene on emotional behaviors. Brain Behav. Immun. 1998, 12, 308-324.
31. De Simone, R., Levi, G., Aloisi, F., Interferon gamma gene expression in rat central nervous system glial cells. Cytokine 1998, 10, 418-422.
32. Rimon, R., Ahokas, A., Hintikka, J., Heikkila, L., Serum interferon in schizophrenia. Ann. Clin. Res. 1985, 17, 139-140.
33. Sistermans, E.A., de Kok, Y.J., Peters, W., Ginsel, L.A. et al., Tissue- and cell-specific distribution of creatine kinase B: a new and highly specific monoclonal antibody for use in immunohistochemistry. Cell Tissue. Res. 1995, 280, 435-446.
34. Olah, J., Orosz, F., Keseru, G.M., Kovari, Z. et al., Triosephosphateisomerase deficiency: a neurodegenerative misfolding disease. Biochem. Soc. Trans. 2002, 30, 30-38.
35. Burbaeva, G., Savushkina, O.K., Boksha, I.S., Creatine kinase BB in brain in schizophrenia. World. J. Biol. Psychiatry 2003, 4, 177-183.
36. Wallimann, T., Dolder, M., Schlattner, U., Eder, M. et al., Creatine kinase: an enzyme with a central role in cellular energy metabolism. MAGMA 1998, 6, 116-119.
37. MacDonald, M.L., Naydenov, A., Chu, M., Matzilevich, D. et al., Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disord. 2006, 8, 255-264.
38. Tachikawa, M., Fukaya, M., Terasaki, T., Ohtsuki, S. et al., Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur. J. Neurosci. 2004, 20, 144-160.
39. Martins-de-Souza, D., Gattaz, W.F., Schmitt, A., Rewerts, C. et al., Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259, 151-163.
40. Williamson, P., Hypofrontality in schizophrenia: a review of the evidence. Can J Psychiatry 1987, 32, 399-404.
41. Kooy, F.H., Hyperglycemia in mental disorders. Brain 1919, 17, 214-289.
42. Braceland, F.J., Meduna, L.J., Vaichulis, J.A., Delayed action of insulin in schizophrenia. Am. J. Psychiatry. 1945, 102, 108-110.
43. Ben-Shachar, D., Laifenfeld, D., Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol. 2004, 59, 273-296.
44. Martins-de-Souza, D., Gattaz, W.F., Schmitt, A., Rewerts, C. et al., Alterations in oligodendrocyte proteins, calcium homeostasis and new potentialmarkersinschizophreniaanteriortemporallobearerevealedbyshotgunproteomeanalysis. J. Neural. Transm. 2009, 116, 275-289.
45. Martins-de-Souza, D., Gattaz, W.F., Schmitt, A., Novello, J.C. et al., Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 2009, 9, 17-24.
46. Martins-de-Souza, D., Gattaz, W.F., Schmitt, A., Maccarrone, G. et al., Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J. Psychiatr. Res. 2009, 43, 978-986.
47. Martins-de-Souza, D., Dias-Neto, E., Schmitt, A., Falkai, P. et al., Proteome analysis of schizophrenia brain tissue. World. J. Biol. Psychiatry. 2010, 11, 110-120.
48. Martins-de-Souza, D., Maccarrone, G., Wobrock, T., Zerr, I. et al., Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J. Psychiatr. Res. 2010, 44, 1176-1189.
49. Hohlfeld, R., Hohlfeld, M., Kerschensteiner, C., Stadelmann, H. et al., The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J. Neuroimmunol. 2000, 107, 161-166.
50. Humphries, A., Ationu, A., Wild, B., Layton, D.M., The consequence of nucleotide substitutions in the triosephosphate isomerase (TPI) gene promoter. Blood Cells Mol. Dis. 1999, 25, 210-217.
51. Pravica, V., Perrey, C., Stevens, A., Lee, J.H. et al., A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum. Immunol. 2000, 61, 863-866.